Janux Therapeutics (JANX) vs LB Pharmaceuticals (LBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed Janux Therapeutics (JANX) over the past year, gaining 130.1% versus a loss of 23.6%. Janux Therapeutics is the larger company by market cap ($1.13 billion vs $1.12 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | LBRX |
|---|---|---|
| Share price | $18.50 | $34.61 |
| Market cap | $1.13B | $1.12B |
| 1-day change | +3.24% | +1.32% |
| YTD return | +34.06% | +55.48% |
| 1-year return | -23.55% | +130.12% |
| 5-year return | -15.19% | — |
| P/E ratio (TTM) | — | 346.10 |
| EPS (TTM) | $-1.64 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $50.16 |
| 52-week low | $12.12 | $14.32 |
| Distance from 52-week high | -47.65% | -31.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +95.89% | +65.56% |
| Average volume | 845.95K | 341.17K |
| Shares outstanding | 61.14M | 32.26M |
| Employees | 113 | 49 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed JANX by 153.7 percentage points over the past year.
- The two companies sit in different sectors: Janux Therapeutics in Healthcare and LB Pharmaceuticals in Health Care.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Healthcare · Biotechnology · 113 employees
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
JANX vs LBRX FAQ
Which is bigger, Janux Therapeutics or LB Pharmaceuticals?
Janux Therapeutics (JANX) is larger, with a market capitalization of $1.13B compared with $1.12B for LB Pharmaceuticals (LBRX).
Which stock has performed better over the past year, JANX or LBRX?
LBRX returned +130.12% over the past 12 months, compared with -23.55% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and LB Pharmaceuticals in the same industry?
No. Janux Therapeutics is in the Healthcare sector, while LB Pharmaceuticals is in Health Care.